Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914679 | 0.95 | KDM4E (0.45) | MEN1KMT2ATRPM4KDM4ELMNA | |
| SCHEMBL6830511 | 0.92 | NHERF1 (0.44) | MEN1KMT2ATRPM4KDM4ELMNA | |
| SCHEMBL6830460 | 0.91 | TRPM4 (0.42) | MEN1KMT2ATRPM4KDM4EGAA | |
| SCHEMBL6834299 | 0.91 | MEN1 (0.56) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL6830741 | 0.90 | ALDH1A1 (0.47) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL6834504 | 0.89 | LMNA (0.47) | MEN1KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6834412 | 0.88 | KDM4E (0.55) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL6835743 | 0.88 | MEN1 (0.42) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL6914683 | 0.88 | NHERF1 (0.39) | MEN1KMT2ATRPM4KDM4ELMNA | |
| SCHEMBL6818890 | 0.87 | TRPV1 (0.46) | TRPM4KDM4ELMNAGAANHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | MEN1 4132/4885KMT2A 2853/4885TRPM4 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.